lebrikizumab

Ligand id: 7684

Name: lebrikizumab

No information available.
Summary of Clinical Use
This antibody was originally tested as a treatment for refractory Hodgkin's lymphoma but was later repurposed as a potential asthma treatment [2]. The antibody entered Phase 2 trial for idiopathic pulmonary fibrosis (IPF) and Phase 3 trial for asthma. Business reports online indicate that Roche have discontinued lebrikizumab development in IPF following mixed results from their trials [1]. Click here to view ClinicalTrails.gov's listing of current lebrikizumab trials.
Mechanism Of Action and Pharmacodynamic Effects
IL-13 induces airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion in allergic lung diseases such as asthma [6]. These changes contribute to airway obstruction. Lebrikizumab was designed to neutralise circulating IL-13, thereby reducing disease symptoms [5].